Literature DB >> 12020728

Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months.

David L King1, Gary W Arendash.   

Abstract

Behavioral characterization of Alzheimer's disease (AD) transgenic models over multiple time points during aging has been largely inadequate, usually being limited to one or two cognitive-based tasks. In this context, the present study utilized a comprehensive 6-week behavioral battery to characterize sensorimotor and cognitive performance of Tg2576 AD transgenic (Tg+) mice and nontransgenic (Tg-) controls aged 3, 9, 14, and 19 months. Compared collectively to Tg- mice over all four time points, Tg+ mice were impaired in Y-maze spontaneous alternation, visible platform recognition, and several sensorimotor tasks; Tg+ mice also showed an overall increase in activity measures. The deficits in visible platform became evident by 9 months of age, while those in sensorimotor tasks became clearly manifest by 14 months. Although the behavioral impairments exhibited by Tg+ mice were usually progressive through 19 months, Tg- animals also showed similar progressive decline in the same behavioral measures; thus, no task revealed a progressive behavioral decline exclusive to Tg+ mice. Moreover, although the 6-week behavioral battery included six cognitively based tasks (i.e., Y-maze, visible platform, Morris water maze, circular platform, passive avoidance, and active avoidance), behavioral analysis through 19 months revealed Tg+ mice to be impaired in only the Y-maze and visible platform tasks. Consequently, Tg2576 mice do not exhibit widespread, profound cognitive impairment, even into old age. This may reflect their predominant C57BL/6 background and an apparent inability of the mutant transgene to profoundly alter performance therein.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12020728     DOI: 10.1016/s0031-9384(02)00639-x

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  85 in total

1.  Preserved fronto-striatal plasticity and enhanced procedural learning in a transgenic mouse model of Alzheimer's disease overexpressing mutant hAPPswe.

Authors:  Silvia Middei; Raffaella Geracitano; Antonio Caprioli; Nicola Mercuri; Martine Ammassari-Teule
Journal:  Learn Mem       Date:  2004 Jul-Aug       Impact factor: 2.460

Review 2.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

3.  Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease.

Authors:  Mark E Bardgett; Natasha N Davis; Patrick J Schultheis; Molly S Griffith
Journal:  Neurobiol Learn Mem       Date:  2010-11-10       Impact factor: 2.877

4.  Characterization of the role of metallothionein-3 in an animal model of Alzheimer's disease.

Authors:  Yasmina Manso; Javier Carrasco; Gemma Comes; Gabriele Meloni; Paul A Adlard; Ashley I Bush; Milan Vašák; Juan Hidalgo
Journal:  Cell Mol Life Sci       Date:  2012-06-22       Impact factor: 9.261

5.  Cross-species translation of the Morris maze for Alzheimer's disease.

Authors:  Katherine L Possin; Pascal E Sanchez; Clifford Anderson-Bergman; Roland Fernandez; Geoffrey A Kerchner; Erica T Johnson; Allyson Davis; Iris Lo; Nicholas T Bott; Thomas Kiely; Michelle C Fenesy; Bruce L Miller; Joel H Kramer; Steven Finkbeiner
Journal:  J Clin Invest       Date:  2016-01-19       Impact factor: 14.808

6.  5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease.

Authors:  Jin Chu; Phillip F Giannopoulos; Carolina Ceballos-Diaz; Todd E Golde; Domenico Praticò
Journal:  Ann Neurol       Date:  2012-09       Impact factor: 10.422

7.  Innate immunity receptor CD36 promotes cerebral amyloid angiopathy.

Authors:  Laibaik Park; Joan Zhou; Ping Zhou; Rose Pistick; Sleiman El Jamal; Linda Younkin; Joseph Pierce; Andrea Arreguin; Josef Anrather; Steven G Younkin; George A Carlson; Bruce S McEwen; Costantino Iadecola
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

8.  Reduced IGF-1 signaling delays age-associated proteotoxicity in mice.

Authors:  Ehud Cohen; Johan F Paulsson; Pablo Blinder; Tal Burstyn-Cohen; Deguo Du; Gabriela Estepa; Anthony Adame; Hang M Pham; Martin Holzenberger; Jeffery W Kelly; Eliezer Masliah; Andrew Dillin
Journal:  Cell       Date:  2009-12-11       Impact factor: 41.582

9.  gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease.

Authors:  Lutgarde Serneels; Jérôme Van Biervliet; Katleen Craessaerts; Tim Dejaegere; Katrien Horré; Tine Van Houtvin; Hermann Esselmann; Sabine Paul; Martin K Schäfer; Oksana Berezovska; Bradley T Hyman; Ben Sprangers; Raf Sciot; Lieve Moons; Mathias Jucker; Zhixiang Yang; Patrick C May; Eric Karran; Jens Wiltfang; Rudi D'Hooge; Bart De Strooper
Journal:  Science       Date:  2009-03-19       Impact factor: 47.728

10.  Sex-related dimorphism in dentate gyrus atrophy and behavioral phenotypes in an inducible tTa:APPsi transgenic model of Alzheimer's disease.

Authors:  Tatiana Melnikova; DaMin Park; Lauren Becker; Deidre Lee; Eugenia Cho; Nuzhat Sayyida; Jing Tian; Karen Bandeen-Roche; David R Borchelt; Alena V Savonenko
Journal:  Neurobiol Dis       Date:  2016-08-26       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.